West Pharmaceutical Services
WST stock analysis · Health Care · Health Care Supplies
As of · fund-implied per-share value
Fund holding value ÷ shares held. Not a live quote; not adjusted for later stock splits.
View SEC fund filing ↗Price × SEC outstanding shares. Shares measured 2026-06-30. Approximate; share and price dates can differ.
View share-count filing ↗DCF value
Equity cash-flow scenario · SEC outstanding shares at 2026-06-30 · -71.8% versus input cap
How this is calculated ↗Reverse DCF
Annual basis · read assumptions below
How this is calculated ↗Relative valuation
52 sector peers · median 25.6×
How this is calculated ↗Historical multiples
7 annual observations · snapshot P/E 51.2× · 15.9% versus history
How this is calculated ↗Free cash flow yield
Annual basis · read assumptions below
How this is calculated ↗ROIC / quality
Normalized tax · financing-capital proxy · parent-equity fallback (scope limitation) · short-term borrowing coverage incomplete
How this is calculated ↗Value composite
Annual basis · read assumptions below
How this is calculated ↗12–1 price momentum
Split and corporate-action verification is incomplete for these fund observations. Verified adjusted endpoints are required for 12–1 momentum.
How this is calculated ↗Asset growth
Annual basis · read assumptions below
How this is calculated ↗Net payout yield
Annual basis · read assumptions below
How this is calculated ↗Accrual quality
Parent-earnings fallback versus consolidated cash flow · scope limitation
How this is calculated ↗Fundamental momentum
Annual basis · read assumptions below
How this is calculated ↗Follow the cash
ANNUAL · USDOperating cash flow and reinvestment over time
Annual USD. Negative bars use a compressed lower scale. Hover or inspect the financial history table for exact values.
Make the assumptions yours
How sensitive is the valuation?
| Return / Growth | 3.0% | 5.0% | 7.0% |
|---|---|---|---|
| 8.0% | $126.89 | $138.45 | $150.88 |
| 10.0% | $92.98 | $101.16 | $109.95 |
| 12.0% | $73.36 | $79.60 | $86.29 |
Annual financial history
Open SEC filings ↗| Fiscal year-end | Revenue | Net income | Operating cash flow | Capital expenditure | Assets |
|---|---|---|---|---|---|
| 2025-12-31 | 3.1B | 493.7M | 754.8M | 285.9M | 4.3B |
| 2024-12-31 | 2.9B | 492.7M | 653.4M | 377M | 3.6B |
| 2023-12-31 | 2.9B | 593.4M | 776.5M | 362M | 3.8B |
| 2022-12-31 | 2.9B | 585.9M | 724M | 284.6M | 3.6B |
| 2021-12-31 | 2.8B | 661.8M | 584M | 253.4M | 3.3B |
| 2020-12-31 | 2.1B | 346.2M | 472.5M | 174.4M | 2.8B |
| 2019-12-31 | 1.8B | 241.7M | 367.2M | 126.4M | 2.3B |
| 2018-12-31 | 1.7B | 206.9M | 288.6M | 104.7M | 2B |
USD, abbreviated. Restated annual history; not a point-in-time backtest. Missing values appear as dashes.
Trace the inputs
MODEL ANNUAL PERIOD| Input | Value | SEC tag / source | Filed |
|---|---|---|---|
| revenue | 3.1B | RevenueFromContractWithCustomerExcludingAssessedTax | 2026-02-17 |
| netIncome | 493.7M | NetIncomeLoss Parent-attributable fallback: a verified consolidated total is unavailable in the supported tags. Noncontrolling interests have not been assumed to be zero; this may differ in scope from consolidated cash flow or operating income. | 2026-02-17 |
| Parent/common earnings proxy | 493.7M | NetIncomeLoss | 2026-02-17 |
| cfo | 754.8M | NetCashProvidedByUsedInOperatingActivities | 2026-02-17 |
| capex | 285.9M | PaymentsToAcquirePropertyPlantAndEquipment | 2026-02-17 |
| operatingIncome | 584.9M | OperatingIncomeLoss | 2026-02-17 |
| assets | 4.3B | Assets | 2026-02-17 |
| equity | 3.2B | StockholdersEquity Parent-attributable fallback: a verified consolidated total is unavailable in the supported tags. Noncontrolling interests have not been assumed to be zero; this may differ in scope from consolidated cash flow or operating income. | 2026-02-17 |
| Parent book equity proxy | 3.2B | StockholdersEquity | 2026-02-17 |
| debt | 202.8M | LongTermDebt | 2026-02-17 |
| shortDebt | — | Not reported under a supported tag | — |
| cash | 791.3M | CashAndCashEquivalentsAtCarryingValue | 2026-02-17 |
| shares | 72.7M | WeightedAverageNumberOfDilutedSharesOutstanding | 2026-02-17 |
| dividends | 61.2M | PaymentsOfDividendsCommonStock | 2026-02-17 |
| buybacks | 134M | PaymentsForRepurchaseOfCommonStock | 2026-02-17 |
| issuance | 18.2M | Reviewed manual correction Bounded FY2025-12-31 consolidated financing-statement extraction. Proceeds from stock-based compensation awards: 11300000 USD [us-gaap:ProceedsFromStockOptionsExercised]; Employee stock purchase plan contributions: 6900000 USD [us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans]. All 9 financing lines reconcile exactly to reported financing cash flow -185100000 USD. Cash inflows from common shares, employee plans and option exercises are summed once as displayed on the statement; noncash compensation, withholding payments, preferred and noncontrolling interests are excluded. This review applies only to this issuer and fiscal period. Source limitation: issuance follows the separately reported common cash-inflow lines; it is not an independent verification of every gross equity transaction. | 2026-02-17 |